Here we have a story with lots of facts, but not a coherent message to consumers about whether zinc lozenges are of any benefit
in shortening cold symptoms. The title and early comments suggest this single retrospective review of existing research gives evidence that larger doses of zinc are effective, but the author of the study says more research is needed. The story’s own independent voice says this is not conclusive at all. Consumers are left without the context to evaluate this latest report.
One researcher estimates that Americans spend about $40 billion per year on both over-the-counter treatments and visits to the doctor for the common cold. No wonder that any new publication should gain wide attention, but the new study (examining old studies) concluded “The effects of zinc lozenges should be further studied to determine the optimal lozenge compositions…” This story shortchanges the consumer by presenting information without much context. It exaggerates the evidence and implies that zinc is an answer.
The story does not mention cost. But zinc lozenges are not expensive, costing perhaps $5 – $10 for a course of treatment.
The story gives us many figures, but it may not reveal enough for a consumer to gain much insight on benefits. It says that some clinical trials comparing zinc acetate lozenges to placebo reduced the duration of colds by an average of 42 percent. But other trials, considered by the author of the research article, used zinc salts (not acetate) at a different dosage, and got results more like 20 percent. The story gives information on the duration of a cold in aggregate and in relative but not not absolute terms. Consumers are left without critical details. It could have explained 42% of what? A week?
The story suggests that, “No prior studies showed zinc lozenge use — even up to 150 mg per day — might cause harm aside from bad taste or constipation” We give it a pass since it does note the major side effects seen.
The tone of this story – if reported at all – should have been that a few small studies were analyzed in an area where there have been many questions about effectiveness in the past. Indeed, the story quotes expert Lisa Winston saying “I don’t think the evidence is strong enough… that we can base clinical practice on it.” Great use of an expert to get context, but why not write the whole story to reflect this context? One could have stressed, higher up in the story, that the results are intriguing but not conclusive and based on small sets of patients.
Instead, “may shorten colds” is in the headline. “Still no cure…but there may be a way to shorten misery” in the lede. The story took on a cheerleading tone from the outset where it did not appear warranted.
The story says there’s no “cure” for the common cold “but there may be a way to shorten its misery.” Yet it doesn’t discuss the fact that most colds for most people are self-limiting and of short duration. And what is the average duration of this “misery”?
The story quotes the author of the original journal article and one expert. Neither of these appear to have conflicts of interest.
The story does not talk about existing strategies to relieve cold symptoms, and so, does not satisfactorily place the new research into context. A quick look at the National Institute for Allergies and Infectious Diseases website includes these: resting in bed, drinking plenty of fluids, gargling with warm salt water, using a decongestant or saline nasal spray, among others.
The story mentioned the “popularity of zinc supplements” but never established how popular, widespread are their use and never explained if the lozenges on market shelves are at the same dosages as discussed in the story.
We can’t give it a satisfactory score; we’ll rule it N/A.
There is nothing novel about zinc lozenges as an over-the-counter aid for cold symptoms. The story is about research reviewing previously published articles on the use of zinc lozenges.
The story does not rely solely on a news release.
Systematic, Criteria-Driven
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Why we should still miss healthnewsreview. https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like